PICALM

Across TCGA pan-cancer cohorts, PICALM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PICALM data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PICALM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PICALM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where PICALM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.647	0.914	.002	28	view →
CCRCC	OS	Median	All	0.983	0.905	.029	9	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
HNSC	OS	Quartile	III,IV	1.000	0.418	.036	8	view →
GBM	OS	Tertile	All	0.787	0.948	.005	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PICALM–LSCC (OS)

Open the LSCC breakdown →